

Patient: SEITHALIL, AMELIA

Patient ID: 60612-1

Patient DOB: 10/16/2003

Sex: Female

Status: Final Review

Ordered: 10/29/2024 11:16 AM by Jennifer Logan

Collected: 10/29/2024 11:16 AM

Reported: 10/31/2024 11:45 PM

Reviewed: 11/01/2024 8:33 AM jlo

Lab Result Status: Final results

Receiving Facility: 361170

Performing Lab: PathGroup

Requisition: 602922

Accession: 24C204N50NLAB

Varicella Zoster Virus (VZV) Antibodies, IgG/IgM

VZVGM

Test performed by PathGroup Labs, LLC
1010 Airpark Center Dr., Suite C, Nashville, TN 37217
Benton R. Middleman, MD, Laboratory Director
CLIA: 44D1008678
AND
Test performed by ARUP Laboratories
500 Chipeta Way, Salt Lake City, UT 84108
Sherrie L Perkins, MD, Laboratory Director

Specimen

Test Performed	Result	Flag	Normal Range	Result Status
Varicella Zoster Virus (VZV) Antibody, IgG	114.7	L	>165.0 Index	F
VZV INTERPRETATION OF RESULTS < 135.0 Non-immune/Non-reactive 135.0-165.0 Equivocal > 165.0 Immune/Reactive A positive result generally indicates exposure to the pathogen or administration of specific immunoglobulins, but it is not indicative of active infection or stage of disease.				
Varicella-Zoster Virus Antibody, IgM	0.16		<=0.90 ISR	F

CBC With Platelet And Differential

CBCWD

Specimen

Measles Mumps Rubella (MMR) Immune Status Panel

IMSPR

Specimen

Test Performed	Result	Flag	Normal Range	Result Status
Rubella Antibody, IgG	73.1		>9.9 IU/mL	F
INTERPRETATION OF RESULTS				
< 10.0 Non-immune/Non-reactive				
≥ 10.0 Immune/Reactive				
Presence of antibodies to Rubella is presumptive evidence of immunity except when acute infection is suspected.				
Measles (Rubeola) Antibody IgG	12.9	L	>16.5 AU/mL	F
INTERPRETATION OF RESULTS				
< 13.5 Non-reactive				
13.5-16.5 Equivocal				
> 16.5 Reactive				
Presence of antibodies to Rubeola is presumptive evidence of immunity except when acute infection is suspected.				
Mumps Antibody IgG	<5.00	L	>10.9 AU/mL	F
INTERPRETATION OF RESULTS				
< 9.0 Non-immune/Non-reactive				
9.0-10.9 Equivocal				
> 10.9 Immune/Reactive				
Immune/Reactive Presence of antibodies to Mumps is presumptive evidence of immunity except when acute infection is suspected.				

PDF Report

0PDF

INTERPRETIVE INFORMATION: Varicella-Zoster Virus Antibody, IgM

- 0.90 ISR or less Negative - No significant level of detectable varicella-zoster virus IgM antibody.
- 0.91-1.09 ISR Equivocal - Repeat testing in 10-14 days may be helpful.
- 1.10 ISR or greater Positive - Significant level of detectable varicella-zoster

virus IgM antibody. Indicative of current or recent infection. However, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection or immunization.

Performed By: ARUP Laboratories
500 Chipeta Way
Salt Lake City, UT 84108
Laboratory Director: Jonathan R. Genzen, MD, PhD
CLIA Number: 46D0523979
Test performed by PathGroup Labs, LLC
1010 Airpark Center Dr., Suite C, Nashville, TN 37217
Benton R. Middleman, MD, Laboratory Director
CLIA: 44D1008678

Test Performed	Result	Flag	Normal Range	Result Status
<u>24C204N50NLAB.PDF</u>				

Result Statuses:

F = Final results

Test Performed	Result	Flag	Normal Range	Result Status
WBC	6.2		3.8-11.5 K/uL	F
Red Blood Cell Count (RBC)	4.35		3.60-5.30 M/mm3	F
Hemoglobin (Hgb)	13.3		11.5-15.5 gm/dL	F
Hematocrit (HCT)	41.1		35.2-46.4 %	F
MCV	94.5		79.0-99.0 fL	F
MCH	30.6		26.9-35.0 pg	F
MCHC	32.4		30.4-34.8 g/dL	F
RDW	45.8		38.6-53.8 fL	F
Platelet Count	296		137-397 K/cumm	F
Neutrophils Automated	64.0		41.0-77.0 %	F
Lymphocytes Automated	25.0		14.0-48.0 %	F
Monocytes Automated	9.8		4.0-13.0 %	F
Eosinophils Automated	0.5		0.0-8.0 %	F
Basophils Automated	0.5		0.0-1.5 %	F
Immature Granulocyte Automated	0.2		0.0-1.0 %	F

Hepatitis B Surface Antibodies (HBsAb) Total

HBSTL

Specimen

Test Performed	Result	Flag	Normal Range	Result Status
Hepatitis B Surface Antibodies (HBsAb) Total	<3.5		mIU/mL	F
Individual is considered to be not immune to infection with HBV.				

Elecsys Anti-HBs Result	Result Interpretation			
<8.5 mIU/mL	Negative			
8.5-11.4 mIU/mL	Indeterminate			
>= 11.5 mIU/mL	Positive			